Compare Abbott Laboratories (ABT) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs ProShares Ultra Gold ETF — how do they compare? Abbott Laboratories trades at $109.35 (market cap $187.95B), while ProShares Ultra Gold ETF trades at $52.46. The key difference: Abbott Laboratories pays a 2.32% dividend while ProShares Ultra Gold ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| ABT | UGL | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $136.62 | $85.62 |
52-Week Low | $82.57 | $34.37 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
UGL trades at $50.69, up 4.45% in 24 hours, with a bullish technical signal driven by moving averages. The stock shows strong momentum but faces overbought conditions with a 6-day RSI at 85.76. Recent news highlights gold's rebound potential, with analysts projecting prices toward $4,500–$5,000 per ounce, benefiting gold-related equities.
The outlook for UGL is positive amid supportive gold market dynamics, though high RSI levels suggest near-term consolidation risks. Investment appeal hinges on sustained gold strength, while exposure to commodity volatility and Fed policy shifts remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
